Dec 04, 2019 / 02:30PM GMT
Umer Raffat - Evercore ISI Institutional Equities, Research Division - Senior MD & Senior Analyst of Equity Research
(technical difficulty)
I guess priorities heading into year-end as well as 2020, and we'll take it from there.
Daniel M. Skovronsky - Eli Lilly and Company - Senior VP & Chief Scientific Officer
Yes. Sure. Well, it's an exciting time at Lilly. Of course, there's a lot of data readouts, that's what gets me the most excited, coming soon. Of course, this is a big week. We have a disclosure coming up at ASH. We have an Alzheimer's portfolio that's moving forward, so we're closely watching what's happening at CTAD as well. Yet by the end of this year, we have beginning of data readouts on Jardiance for heart failure, more of that coming next year. And then next year, we also get to see tirzepatide data. That's our GIP/GLP molecule in Phase III. We'll see the first Phase III readouts next year as well as our first Phase III for an IL-23 in IBD. That's mirikizumab in ulcerative colitis. So a lot to look forward to and a lot going on at
Eli Lilly and Co at Evercore HealthCONx Conference Transcript
Dec 04, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers